Literature DB >> 27480208

Maternal pre-eclampsia as a risk factor for necrotizing enterocolitis.

Lena Perger1,2,3, Dhriti Mukhopadhyay1,4, Luka Komidar5, Katie Wiggins-Dohlvik1,4, Mohammad N Uddin1,6, Madhava Beeram1,3.   

Abstract

OBJECTIVE: Similar pro-inflammatory responses are present in pre-eclampsia (PE) and necrotizing enterocolitis (NEC). We hypothesized that maternal PE is an independent risk factor for the development of NEC.
METHODS: A retrospective database of all live births (2008-2011) at a tertiary center was constructed. Infant and maternal characteristics were gathered. Babies born to mothers with or without PE were compared. Data were analyzed using Mann-Whitney U, Pearson's χ(2), binary logistic regression and relative risks.
RESULTS: Incidence of NEC was 1.5% in non-PE and 4.6% in the PE group (p < 0.001), but once controlled for gestational age and birth weight, the difference lost statistical significance. PE babies were more frequently preterm (41.4% versus 14.5%, p < 0.001) and had intrauterine growth restriction (IUGR) (10.2% versus 6.3%, p < 0.001). Within preterm babies, 9.0% of non-PE and 10.8% of PE babies developed NEC (p = 0.25). Effect of PE was significant in sub-group of IUGR babies, with NEC in 1.5% of non-PE and 13.6% in PE babies (p < 0.001).
CONCLUSIONS: Maternal PE is an independent risk factor for the development of NEC in some sub-groups of babies, most notably with IUGR. Fetal hypoxia caused by abnormal placentation in PE leads to restricted growth, and may be the underlying mechanism that predisposes the newborn to NEC.

Entities:  

Keywords:  Necrotizing enterocolitis; newborn; pre-eclampsia; small for gestational age

Mesh:

Year:  2015        PMID: 27480208     DOI: 10.3109/14767058.2015.1076386

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  8 in total

1.  Differential effects of delivery hospital on mortality and morbidity in minority premature and low birth weight neonates.

Authors:  Gia Yannekis; Molly Passarella; Scott Lorch
Journal:  J Perinatol       Date:  2019-06-24       Impact factor: 2.521

Review 2.  Recent Advances in Necrotizing Enterocolitis Research: Strategies for Implementation in Clinical Practice.

Authors:  Mohan Pammi; Isabelle G De Plaen; Akhil Maheshwari
Journal:  Clin Perinatol       Date:  2020-03-04       Impact factor: 3.430

3.  ELABELA plasma concentrations are increased in women with late-onset preeclampsia.

Authors:  Bogdan Panaitescu; Roberto Romero; Nardhy Gomez-Lopez; Percy Pacora; Offer Erez; Felipe Vadillo-Ortega; Lami Yeo; Sonia S Hassan; Chaur-Dong Hsu
Journal:  J Matern Fetal Neonatal Med       Date:  2018-07-22

4.  Maternal, fetal and perinatal factors associated with necrotizing enterocolitis in Sweden. A national case-control study.

Authors:  Margareta Ahle; Peder Drott; Anders Elfvin; Roland E Andersson
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

5.  Editorial: Intestinal Microbiota in the Pathogenesis and Management of Necrotizing Enterocolitis in Preterm Infants.

Authors:  Chunbao Guo; Yuan Shi
Journal:  Front Pediatr       Date:  2022-02-17       Impact factor: 3.418

6.  Impact of early-onset preeclampsia on feeding tolerance and growth of very low birth weight infants during hospitalization.

Authors:  Simone Manso de Carvalho Pelícia; Saskia Maria Wiegerinck Fekete; Jose Eduardo Corrente; Ligia Maria Suppo de Souza Rugolo
Journal:  Rev Paul Pediatr       Date:  2022-09-09

7.  Predictive Factors for Surgical Intervention in Neonates with Necrotizing Enterocolitis: A Retrospective Study.

Authors:  Lei Yu; Chao Liu; Qingjing Du; Lishuang Ma
Journal:  Front Surg       Date:  2022-05-17

8.  Maternal pregnancy-induced hypertension increases subsequent neonatal necrotizing enterocolitis risk: A nationwide population-based retrospective cohort study in Taiwan.

Authors:  Chih-Chieh Yang; Pei-Ling Tang; Po-Yen Liu; Wei-Chun Huang; Ying-Yao Chen; Hsiao-Ping Wang; Jenn-Tzong Chang; Li-Te Lin
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.